<![CDATA[SOT106 Lands Dual FDA Designations for Osteosarcoma and Soft Tissue Sarcoma]]>
The FDA has granted orphan drug designation to SOT106, an investigational antibody-drug conjugate (ADC), for the treatment of patients with soft tissue sarcoma (STS), and fast track designation to the agent for the treatment of patients with osteosarcoma.1 …